GHRSGH ResearchGHRS info
$6.85info-7.31%24h
Global rank13654
Market cap$356.34M
Change 7d-10.10%
YTD Performance16.70%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    GH Research (GHRS) Stock Overview

    GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

    GHRS Stock Information

    Symbol
    GHRS
    Address
    Joshua Dawson HouseDublin, D02 RY95Ireland
    Founded
    -
    Trading hours
    -
    Website
    https://www.ghres.com
    Country
    🇮🇪 Ireland
    Phone Number
    353 1 437 8334

    GH Research (GHRS) Price Chart

    -
    Value:-

    GH Research Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $6.85
    N/A
    Market Cap
    $356.34M
    N/A
    Shares Outstanding
    52.02M
    N/A
    Employees
    32.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org